Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOB1 siRNA
- Development stage
- Preclinical
- Lead developer
- Georgetown University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
TOB1 siRNA is a small interfering RNA designed to target and knock down the expression of the Transducer of ERBB2, 1 (TOB1) gene. In preclinical studies, TOB1 siRNA has been utilized to investigate the role of TOB1 in cell survival, cell cycle regulation, and therapy resistance. Specifically, in estrogen-independent estrogen receptor-positive (ER+) breast cancer models, knockdown of TOB1 using TOB1 siRNA significantly inhibits cell growth, reduces DNA replication, blocks the G1 to S phase transition, and induces DNA damage. Additionally, in lung cancer models, TOB1 siRNA has been shown to modulate radiosensitivity via the MAPK/ERK signaling pathway. TOB1 siRNA is primarily utilized as a research-use-only tool to study tumor suppression and cell cycle dynamics.
- Other names
- siTOB1siTOB-1siTOB 1tob1 siRNAtob-1 siRNAtob 1 siRNATOB1 small interfering RNATOB-1 small interfering RNATOB 1 small interfering RNA
02
Targets
TOB1 (Transducer of ERBB2, 1)
Beyond the preview
Go deeper on TOB1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOB1 siRNA.